logo
logo

Mauna Kea Technologies signs Half-year Liquidity Contract for H1 2024 with Brokerage Firm Gilbert Dupont

Mauna Kea Technologies signs Half-year Liquidity Contract for H1 2024 with Brokerage Firm Gilbert Dupont

07/17/24, 3:56 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/FR.svgparis
Industry
medical device
biotechnology
health care
manufacturing
Type
contract
Mauna Kea Technologies has signed a liquidity contract with the brokerage firm Gilbert Dupont for the first half of 2024. The contract aims to provide resources for the company as per the half-year statement on June 28, 2024.

Company Info

Company
Mauna Kea Technologies
Location
paris, ile de france, france
Additional Info
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions.